Drug Database · Clinicians

Hydroxyzine

Brands (6) Droxiem, Evazine, Sedazine…Show all

US brand (reference label): Hydroxyzine Hydrochloride; not a Philippine-registered brand.

Antihistamine (h1-receptor antagonist); Anxiolytic PH FDA category

Rx · Prescription drug10 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 9ef6a4b7-362d-61b4-e053-2995a90a0ebb, version date July 28, 2026 (Hydroxyzine Hydrochloride · St Mary's Medical Park Pharmacy). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus.

As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.

The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

Contraindications

CONTRAINDICATIONS Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride. Hydroxyzine is contraindicated in patients with a prolonged QT interval.

Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.

Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: adults, 50 to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses. For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg for adults and 0.6 mg/kg of body weight in children. When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally. As with all potent medication, the dosage should be adjusted according to the patient’s response to therapy.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. The extent of renal excretion of hydroxyzine has not been determined.

Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.

Dosage forms

Philippines

  • Tablet: 10 mg, 25 mg
  • Film-coated tablet: 10 mg, 25 mg
  • Solution for injection: 50 mg/mL

Registered products in the Philippines

10 products registered with the Food and Drug Administration (FDA) Philippines list Hydroxyzine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products10
Philippine FDA-registered products for Hydroxyzine
Package insert
DroxiemHydroxyzine Hydrochloride
25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Norris Medicines LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-11885
Sep 27, 2028
DroxiemHydroxyzine Hydrochloride
50 mg/mL Solution For Injection (IM)Amber Glass Ampoule x 1 mL & 2 mL (Box of 10's)
Rx
Norris Medicine Ltd.India
Zyre Pharmaceuticals CorporationImporter: Medethix, Inc.Trader: Augmen Pharma, LLP
DRP-4687
Oct 21, 2031
EvazineHydroxyzine Hydrochloride
50 mg/mL Solution for Injection (IM)Amber Glass Ampoule x 1 mL (Box of 10's); Amber Glass Ampoule x 2 mL (Box of 10's)
Rx
Norris Medicines LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-4684
Sep 6, 2028
NoneHydroxyzine (as Hydrochloride)
10 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc.
DR-XY41323
Oct 18, 2031
NoneHydroxyzine (as Hydrochloride)
10 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
UNILAB, Inc.Philippines
—
DR-XY36140
Jul 28, 2029
NoneHydroxyzine Hydrochloride
25 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
Rx
UNILAB, Inc.Philippines
—
DRP-1772
Dec 9, 2029
SedazineHydroxyzine Hydrochloride
10 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Vamsler Phils. Inc.
DRP-7082
Dec 12, 2027
Sedazine 25Hydroxyzine Hydrochloride
25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Norris Medicines LimitedIndia
Vamsler Phils. Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-11885-02
Sep 27, 2028
ZiltemHydroxyzine Hydrochloride
25 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Norris Medicines LimitedIndia
EMCURE PHARMA PHILIPPINES INC.Importer: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-11885-01
Sep 27, 2028
Ziltem IMHydroxyzine Hydrochloride
50 mg/mL Solution for Injection (IM)Amber Glass Ampoule x 1 mL (Box of 10's)
Rx
Norris Medicines LimitedIndia
Emcure Pharma Philippines Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-4684-01
Sep 6, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature. Anticholinergic: Dry mouth. Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended.

Clinically significant respiratory depression has not been reported at recommended doses. Cardiac System: QT prolongation, Torsade de Pointes. In postmarketing experience, the following additional undesirable effects have been reported: Body as a Whole: Allergic reaction. Nervous System: Headache. Psychiatric: Hallucination.

Skin and Appendages: Oral hydroxyzine is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in postmarketing reports; pruritus, rash, urticaria.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system. Primary skeletal muscle relaxation has been demonstrated experimentally.

Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated. Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine’s clinical effects are usually noted within 15 to 30 minutes after oral administration.

Formulary and pricing (Philippines)

Formulary and coverage

Philippine National FormularyListed as Hydroxyzine (as dihydrochloride)
PNF listingOral: 25 mg tablet
PNF listingOral: 2 mg/mL syrup, 100 mL
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Hydroxyzine Hydrochloride · St Mary's Medical Park Pharmacy [US FDA-approved label, version 5, July 28, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef6a4b7-362d-61b4-e053-2995a90a0ebb
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .